BCL2 and ovarian carcinoma: Shuai Wu et al.15found that inactivation of ARID1A, the most common mutant subunit of the SWI/SNF complex in tumours, caused resistance to EZH2 inhibitors, but was sensitive to BCL2 inhibitors, and that the combination of BCL2 and EZH2 inhibitors gave good therapeutic results in a mouse ovarian cancer model.